For patients treated with Xtandi plus leuprolide versus placebo plus leuprolide, EMBARK met the key secondary endpoint with a statistically significant and clinically meaningful improvement in OS.
There was a favorable trend in results towards improved OS for patients treated with Xtandi monotherapy versus placebo plus leuprolide; however, the difference did not reach statistical significance.
No new safety signals were observed in the analysis, and the safety results were consistent with Xtandi’s demonstrated safety profile.
In the EMBARK study, patients were randomized to one of three study arms: Xtandi plus leuprolide, placebo plus leuprolide or XTANDI monotherapy.
The most common adverse events (occurring in ≥10% of patients) in the combination group and the leuprolide-alone group were hot flashes and fatigue. The most common adverse events in the monotherapy group were gynecomastia, hot flashes, and fatigue.
Xtandi is approved in over 80 countries, including the U.S., the EU and Japan.
Detailed OS results from EMBARK will be presented at a future medical meeting.
In March, the U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG's (NYSE:NVS) Pluvicto for prostate cancer patients.
The expanded indication, which approximately triples the number of patients eligible to receive Pluvicto, is based on the Phase 3 PSMAfore trial results.
Novartis is investigating Pluvicto in earlier stages of the disease, including metastatic hormone-sensitive prostate cancer and oligometastatic prostate cancer.
PFE, ALPMY Price Actions: Pfizer stock is up 1.13% at $25.85; Astellas is down 0.64% at $9.40 at publication on Thursday.
Read Next:
Photo: Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
